Studies from Baptist Health South Florida Further Understanding of Brain Cancer (Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial...).

A recent study conducted by researchers at Baptist Health South Florida explored the efficacy and safety of the base excision repair inhibitor TRC102 in combination with temozolomide (TMZ) for patients with recurrent glioblastoma (GBM). The study involved a phase 2 clinical trial called BERT, which enrolled 19 bevacizumab-naive GBM patients at first recurrence. The primary endpoint of the trial was response rates, but objective responses were not observed, and a second arm of the trial was not opened. The study found that the combination therapy was safe and feasible for patients with recurrent GBM, and further evaluation of combination therapy in biomarker-enriched trials is warranted. [Extracted from the article]